Immunic (in discussions with Roche) plans to conduct FDA regulatory meetings for two...
NURTEC (Rimegepant) for the Acute Treatment of Migraine
NURTECTM (Rimegepant) is the only calcitonin gene-related peptide (CGRP) receptor antagonist indicated for acute treatment of migraine in adults.
resTORbio reports interim data from Parkinson’s trial
resTORbio has reported positive interim findings from three cohorts in the Phase Ib/II clinical trial of RTB101 in patients with Parkinson’s disease.
Teva’s deutetrabenazine fails in paediatric Tourette syndrome trials
Results from Teva Pharmaceutical Industries have revealed that deutetrabenazine did not meet the primary endpoint in Phase II/III ARTISTS 1 and Phase III ARTISTS 2 studies involving pediatric patients with moderate to severe Tourette syndrome.
UCL researchers test cough syrup drug for Parkinson’s
A research team at University College London has secured funding to evaluate the use of cough syrup drug ambroxol to treat Parkinson’s disease patients in clinical trials.
Annovis Bio to continue DISCOVER Alzheimer’s trial
Drug platform company Annovis Bio is set to continue its Phase II DISCOVER clinical trial of ANVS401 in patients suffering from Alzheimer’s disease.
Biohaven reports Phase III data of troriluzole in anxiety patients
Biohaven Pharmaceutical has reported that troriluzole missed the primary endpoint of the Phase III clinical trial conducted in generalised anxiety disorder (GAD) patients.
Lilly’s solanezumab fails to meet Phase II/III goal in Alzheimer’s
Eli Lilly has reported top-line data from the Phase II/III DIAN-TU clinical trial of solanezumab in patients with autosomal dominant Alzheimer's disease/dominantly inherited Alzheimer's disease (DIAD) caused by rare gene mutations.
Trevena resubmits new drug application to USFDA for Oliceridine
Biopharmaceutical company Trevena has resubmitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for IV oliceridine.
Roche’s gantenerumab fails in Phase II/III inherited Alzheimer’s trial
Top-line results from Roche’s Phase II/III DIAN-TU-001 clinical trial of gantenerumab showed that the drug failed to meet its primary goal in patients with an early-onset, inherited form of Alzheimer’s disease (AD).
Zogenix’s Fintepla meets Phase III goal in Lennox-Gastaut patients
Top-line results from the Phase III clinical trial of Zogenix’s Fintepla have demonstrated that the primary endpoint was met in patients with Lennox-Gastaut Syndrome (LGS), a type of childhood-onset epilepsy.